viewNaturally Splendid Enterprises Ltd.

Naturally Splendid answers Health Canada questions in progress toward Phase 2 coronavirus trial of cavaltinib

The questions from Health Canada are considered a formality, the company said

Person wearing PPE using microscope
The lingering questions for Plasm concern the dosage of cavaltinib to be administered during the trial

Naturally Splendid Enterprises Ltd (CVE:NSP) (OTCMKTS:NSPDF) (FRA:50N), which is developing a coronavirus (COVID-19)  treatment through a joint venture with Biologic Pharmamedical Research, responded to an information request notice from Health Canada, the company announced Friday. 

The joint venture, Plasm Pharmaceutical, is preparing for a phase 2 coronavirus trial of its drug cavaltinib, and the questions from Health Canada are considered a formality, the company said. 

"This COVID crisis is not going to end anytime soon,” Biologic founder and Plasm Pharmaceutical lead researcher Franco Cavaleri said in a statement. “Although a vaccine will be the ultimate solution to the pandemic, we need alternative more immediate treatment strategies to reduce the degree of morbidity and risk of mortality for those who are vulnerable today. In this regard, we have been in dialogue with Health Canada to develop a final functional mutually acceptable phase 2 clinical trial for a COVID treatment, utilizing our Cavaltinib technology as the test drug.”

READ: Naturally Splendid debuts new website as it prepares to roll out a slew of new plant-based products in North America

The lingering questions for Plasm concern the dosage of cavaltinib to be administered during the trial.

“On October 2, 2020, we responded to the latest information request notice (IRN) from Health Canada,” Cavaleri said. “The IRN was designed to determine the final dosage of cavaltinib intended for use as a COVID treatment and to define the final criteria for the selection of patients making up the test and control groups for the trial. We have complied [with] the last requests made by Health Canada with regards to the experimental protocol and look forward to a final reply from Health Canada on these matters."

The company previously announced that it secured the necessary lab space and supply of cavaltinib to conduct the trial, in addition to significant manufacturing capacity in Canada and the US, should things go to plan.

Health Canada previously issued what is called a 'no objection' letter for cavaltinib, in response to Biologic’s clinical trial application for the drug.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Quick facts: Naturally Splendid Enterprises Ltd.

Price: 0.045 CAD

Market: TSX-V
Market Cap: $9.08 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Naturally Splendid Enterprises Ltd. named herein, including the promotion by the Company of Naturally Splendid Enterprises Ltd. in any Content...


Naturally Splendid signs deal with another food distributer for their Natera...

Naturally Splendid (CVE: NSP- OTC: NSPDF) President and CEO Craig Goodwin joined Steve Darling from Proactive with news the company has signed another distribution deal for 3 of their Natera Plant-Based foods. Goodwin telling Proactive the new distributor will be stocking schnitzel and two...

4 days, 2 hours ago

2 min read